3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
18
Paclitaxel
17
Bevacizumab
17
olaparib
8
Specimen Handling
7
liposomal doxorubicin
6
pembrolizumab
5
Taxes
5
Biopsy
5
cemiplimab
4
Magnetic Resonance Spectroscopy
4
sarilumab
3
niraparib
3
mirvetuximab soravtansine
3
Topotecan
3
Standard of Care
3
Letrozole
3
Gemcitabine
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
taxane
2
talazoparib
2
palbociclib
2
abemaciclib
2
Temozolomide
2
Surgical Procedures, Operative
2
Practice Guidelines as Topic
2
Poly(ADP-ribose) Polymerase Inhibitors
2
Palliative Care
2
Immunoglobulin G
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Fallopian Tube Neoplasms
×
Histamine H2 Antagonists
×
Clear all
NCT06824467
2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3
Recruiting
770 enrolled